RT Journal Article
SR Electronic
T1 Utility of Genome Sequencing After Nondiagnostic Exome Sequencing in Unexplained Pediatric Epilepsy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.08.24307445
DO 10.1101/2024.08.08.24307445
A1 D’Gama, Alissa M.
A1 Shao, Wanqing
A1 Smith, Lacey
A1 Koh, Hyun Yong
A1 Davis, Maya
A1 Koh, Julia
A1 Oby, Brandon T.
A1 Urzua, Cesar I.
A1 Sheidley, Beth R.
A1 Rockowitz, Shira
A1 Poduri, Annapurna
YR 2024
UL http://medrxiv.org/content/early/2024/08/09/2024.08.08.24307445.abstract
AB Importance Epilepsy is the most common neurological disorder of childhood. Identifying genetic diagnoses underlying epilepsy is critical to developing effective therapies and improving outcomes. Most children with non-acquired (unexplained) epilepsy remain genetically unsolved, and the utility of genome sequencing after nondiagnostic exome sequencing is unknown.Objective To determine the diagnostic (primary) and clinical (secondary) utility of genome sequencing after nondiagnostic exome sequencing in individuals with unexplained pediatric epilepsy.Design This cohort study performed genome sequencing and comprehensive analyses for 125 participants and available biological parents enrolled from August 2018 to May 2023, with data analysis through April 2024 and clinical return of diagnostic and likely diagnostic genetic findings. Clinical utility was evaluated.Setting Pediatric referral centerParticipants Participants with unexplained pediatric epilepsy and previous nondiagnostic exome sequencing; biological parents when availableExposure(s) Short-read genome sequencing and analysisMain Outcome(s) and Measure(s) Primary outcome measures were the diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding, and the unique diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding that required genome sequencing. The secondary outcome measure was clinical utility of genome sequencing, defined as impact on evaluation, treatment, or prognosis for the participant or their family.Results 125 participants (58 [46%] female) were enrolled with median age at seizure onset 3 [IQR 1.25, 8] years, including 44 (35%) with developmental and epileptic encephalopathies. The diagnostic yield of genome sequencing was 7.2% (9/125), with diagnostic genetic findings in five cases and likely diagnostic genetic findings in four cases. Among the solved cases, 7/9 (78%) required genome sequencing for variant detection (small copy number variant, three noncoding variants, and three difficult to sequence small coding variants), for a unique diagnostic yield of genome sequencing of 5.6% (7/125). Clinical utility was documented for 4/9 solved cases (44%).Conclusions and Relevance These findings suggest that genome sequencing can have diagnostic and clinical utility after nondiagnostic exome sequencing and should be considered for patients with unexplained pediatric epilepsy.Question What is the utility of genome sequencing after nondiagnostic exome sequencing in individuals with unexplained pediatric epilepsy?Findings In this cohort study of 125 individuals with unexplained pediatric epilepsy and nondiagnostic exome sequencing, genome sequencing identified diagnostic genetic findings in five cases and likely diagnostic genetic findings in four cases. Of the nine solved cases, seven required genome sequencing to solve, and four had documented clinical utility.Meaning Genome sequencing can identify genetic diagnoses not detectable by exome sequencing and should be considered for participants with unexplained pediatric epilepsy, as first-line testing or after nondiagnostic exome sequencing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the BCH Children's Rare Disease Collaborative and the Robinson Fund for Transformative Research in Epilepsy. AMD was supported by T32 HD098061 from the NIH/NICHD and the Hearst Foundation Fellowship from Harvard Medical School.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Boston Children's Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDeidentified participant data will be made available on request to the corresponding author. Data will be made available for research purposes to investigators whose protocols allow use of deidentified phenotypic and genomic data with a signed data use agreement.